Segment and Other Revenue Information (Income Statement Narrative) (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues denominated in Euros	$ 710		$ 693		$ 639
Restructuring charges	(17)		(5)		(52)
Investor Related Costs	5
Gain (Loss) on Disposition of Assets	9	[1]	6	[1]	0	[1]
Asset write-offs and asset impairments	10		15		10
Additional depreciation asset restructuring	0	[2]	5	[2]	0	[2]
Inventory and Intercompany Write Offs After Separation			24
Gain (loss) related to litigation settlement	(10)	[3]	(1)	[3]	19	[3]
Insurance Recoveries	2
Percentage Of Total Revenues By Country	10.00%
Revenue By Major Customer, Percentage	11.00%		10.00%
United States (U.S.)
Segment Reporting Information [Line Items]
Restructuring charges	(2)
Certain Significant Items
Segment Reporting Information [Line Items]
Restructuring charges			20
Stand-up costs	168		206
Gain (Loss) on Disposition of Assets	3
Restructuring Costs and Asset Impairment Charges			19
Charges for manufacturing services agreements associated with divestitures change in estimate					4
Restructuring and implementation costs					115
Additional depreciation asset restructuring	1		8
Gain (loss) related to litigation settlement			5
Manufacturing, Research, Corporate [Member]
Segment Reporting Information [Line Items]
Restructuring charges	5		3
MEXICO
Segment Reporting Information [Line Items]
Insurance Recoveries	1
MEXICO | Certain Significant Items
Segment Reporting Information [Line Items]
Gain (loss) related to litigation settlement	13
Insurance Recoveries	1
NETHERLANDS
Segment Reporting Information [Line Items]
Dedicated Pension Plans, Settlement Charge for Contract Termination	4
Other International Countries
Segment Reporting Information [Line Items]
Revenues	100
Employee Severance [Member]
Segment Reporting Information [Line Items]
Restructuring charges	(16)		23		(49)
Employee Severance [Member] | United States (U.S.)
Segment Reporting Information [Line Items]
Restructuring charges	2
Employee Severance [Member] | Europe, Africa, and Middle East (EuAfME)
Segment Reporting Information [Line Items]
Restructuring charges	(12)
Employee Severance [Member] | Manufacturing, Research, Corporate [Member]
Segment Reporting Information [Line Items]
Restructuring charges	(6)
In Process Research and Development [Member]
Segment Reporting Information [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	6
ProductRights [Member] | Certain Significant Items
Segment Reporting Information [Line Items]
Gain (Loss) on Disposition of Assets	2
Intellectual Property
Segment Reporting Information [Line Items]
Gain (loss) related to litigation settlement					$ 14

[1] In 2014, represents the net gain on sale of land in our Taiwan joint venture of $6 million and the net gain on the government-mandated sale of certain product rights in Argentina and China that were associated with the FDAH acquisition in 2009 of $3 million. In 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.

[2] The restructuring charges for the year ended December 31, 2014, are primarily related to:•employee termination costs in EuAfME and in our global manufacturing operations ($18 million);•a reversal of a previously established reserve as a result of a change in estimate of employee termination costs ($2 million benefit); and•exit costs related to the exiting of a certain leased manufacturing facility ($1 million).The restructuring charges (benefits) for the year ended December 31, 2013, are primarily related to: •a reversal of certain employee termination costs associated with our operations in Europe ($27 million benefit); •asset impairment charges related to one of our manufacturing facilities ($17 million); and•restructuring charges related to the exiting of certain leased manufacturing and research facilities consisting of employee termination expenses ($2 million), exit costs ($4 million), and accelerated depreciation ($5 million).The direct restructuring charges (benefits) are associated with the following: •For the year ended December 31, 2014––EuAfME ($12 million) and manufacturing/research/corporate ($5 million). •For the year ended December 31, 2013—EuAfME ($4 million), CLAR ($4 million) and manufacturing/research/corporate ($3 million income). •For the year ended December 31, 2012––EuAfME ($51 million), CLAR ($3 million), APAC ($1 million income) and manufacturing/research/corporate ($1 million income).

[3] In July 2014, we reached a commercial settlement with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. For 2014, includes a $13 million charge recorded in the second quarter of 2014, which was partially offset by a $1 million insurance recovery recorded in the third quarter of 2014, related to the commercial settlement in Mexico. We do not expect any significant additional charges related to this issue. For 2014, also includes an insurance recovery of other litigation-related charges of $2 million. For 2012, represents income from a favorable legal settlement related to an intellectual property matter ($14 million) and a change in estimate for an environmental-related reserve due to a favorable settlement ($7 million income) partially offset by litigation-related charges ($2 million).